Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases

Overview

Journal Endocrinology

Publisher Oxford University Press

Specialty Endocrinology

Date 2023 Oct 12

PMID 37823483

Authors

Sulayman Aslan Lyons

Jacqueline Leah Beaudry

Affiliations

Soon will be listed here.

Abstract

Metabolic diseases, such as obesity, type 2 diabetes mellitus (T2DM), cardiovascular disease, and liver disease, have become increasingly prevalent around the world. As an alternative to bariatric surgery, glucagon-like peptide 1 (GLP-1) receptor agonists have been at the forefront of weight loss medication to combat these metabolic complications. Recently, there has been an exciting rapid emergence of new weight loss medications that combine GLP-1 receptor (GLP-1R) agonists with other gut- and pancreatic-derived hormones, such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) receptor agonists. Dual-agonist (GLP-1/GIP and GLP-1/GCG) and tri-agonist (GLP-1/GIP/GCG) administration generally result in greater weight loss, reduction of blood sugar and lipid levels, restoration of tissue function, and improvement in whole-body substrate metabolism compared to when GLP-1R agonists are used alone. The aim of this review is to summarize the recent literature of both preclinical and clinical studies on how these emerging gut-peptide therapies further improve weight loss and metabolic health outcomes for various metabolic diseases.

Citing Articles

GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms.

Mullur N, Morissette A, Morrow N, Mulvihill E J Endocrinol. 2024; 263(1).

PMID: 39145614 PMC: 11466209. DOI: 10.1530/JOE-24-0046.

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.

Morissette A, Mulvihill E J Pharm Pharm Sci. 2024; 27:13065.

PMID: 38903652 PMC: 11186996. DOI: 10.3389/jpps.2024.13065.

Rising tide: The global surge of type 2 diabetes in children and adolescents demands action now.

Pappachan J, Fernandez C, Ashraf A World J Diabetes. 2024; 15(5):797-809.

PMID: 38766426 PMC: 11099374. DOI: 10.4239/wjd.v15.i5.797.

References

Jastreboff A, Aronne L, Ahmad N, Wharton S, Connery L, Alves B . Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387(3):205-216. DOI: 10.1056/NEJMoa2206038. View

Campbell J . Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms. Mol Metab. 2020; 46:101139. PMC: 8085569. DOI: 10.1016/j.molmet.2020.101139. View

Frias J, Bastyr 3rd E, Vignati L, Tschop M, Schmitt C, Owen K . The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Cell Metab. 2017; 26(2):343-352.e2. DOI: 10.1016/j.cmet.2017.07.011. View

Lamont B, Drucker D . Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes. 2007; 57(1):190-8. DOI: 10.2337/db07-1202. View

Del Prato S, Kahn S, Pavo I, Weerakkody G, Yang Z, Doupis J . Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021; 398(10313):1811-1824. DOI: 10.1016/S0140-6736(21)02188-7. View

Yang B, Gelfanov V, El K, Chen A, Rohlfs R, Dubois B . Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems. Mol Metab. 2022; 66:101638. PMC: 9719863. DOI: 10.1016/j.molmet.2022.101638. View

Lynch C, Adams S . Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014; 10(12):723-36. PMC: 4424797. DOI: 10.1038/nrendo.2014.171. View

Bergmann N, Gasbjerg L, Heimburger S, Krogh L, Dela F, Hartmann B . No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care. 2020; 43(3):588-596. DOI: 10.2337/dc19-0578. View

Getz G, Reardon C . Do the Apoe-/- and Ldlr-/- Mice Yield the Same Insight on Atherogenesis?. Arterioscler Thromb Vasc Biol. 2016; 36(9):1734-41. PMC: 5001905. DOI: 10.1161/ATVBAHA.116.306874. View

10.

Kannt A, Madsen A, Kammermeier C, Elvert R, Klockener T, Bossart M . Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. Diabetes Obes Metab. 2020; 22(8):1328-1338. DOI: 10.1111/dom.14035. View

11.

Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D . Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10402):613-626. DOI: 10.1016/S0140-6736(23)01200-X. View

12.

Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515. DOI: 10.1056/NEJMoa2107519. View

13.

Lingvay I, Mosenzon O, Brown K, Cui X, ONeill C, Lando L . Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023; 22(1):66. PMC: 10039543. DOI: 10.1186/s12933-023-01797-5. View

14.

Thomas M, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K . Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2020; 106(2):388-396. PMC: 7823251. DOI: 10.1210/clinem/dgaa863. View

15.

Troke R, Tan T, Bloom S . The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis. 2014; 5(1):4-14. PMC: 3871274. DOI: 10.1177/2040622313506730. View

16.

Daousi C, Wilding J, Aditya S, Durham B, Cleator J, Pinkney J . Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol (Oxf). 2009; 71(2):195-201. DOI: 10.1111/j.1365-2265.2008.03451.x. View

17.

Vanweert F, Schrauwen P, Phielix E . Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes. Nutr Diabetes. 2022; 12(1):35. PMC: 9356071. DOI: 10.1038/s41387-022-00213-3. View

18.

Del Prato S, Gallwitz B, Holst J, Meier J . The incretin/glucagon system as a target for pharmacotherapy of obesity. Obes Rev. 2021; 23(2):e13372. PMC: 9286339. DOI: 10.1111/obr.13372. View

19.

Boland M, Laker R, Mather K, Nawrocki A, Oldham S, Boland B . Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020; 2(5):413-431. PMC: 7258337. DOI: 10.1038/s42255-020-0209-6. View

20.

Kleinert M, Sachs S, Habegger K, Hofmann S, Muller T . Glucagon Regulation of Energy Expenditure. Int J Mol Sci. 2019; 20(21). PMC: 6862306. DOI: 10.3390/ijms20215407. View